Procarbazine
Also called Ibenzmethyzin, Procarbacine, Benzethyzin
Part of the metabolic pathway of Procarbazine. See the timeline on the metabolic highway.
Overview
Procarbazine is a chemotherapy medication used for the treatment of Hodgkin lymphoma and brain cancers. For Hodgkin lymphoma it is often used together with chlormethine, vincristine, and prednisone while for brain cancers such as glioblastoma multiforme it is used with lomustine and vincristine. It is typically taken by mouth.[1] WP
Common side effect include low blood cell counts and vomiting. Other side effects include tiredness and depression. It is not recommended in people with severe liver or kidney problems. Use in pregnancy is known to harm the baby. Procarbazine is in the alkylating agents family of medication. How it works is not clearly known.[1–4] WP
Procarbazine was approved for medical use in the United States in 1969. It is on the World Health Organization's List of Essential Medicines. In the United Kingdom a month of treatment cost the National Health Service 450 to 750 pounds.[1]
Uses, dosage and effects
Medical uses
When used to treat Hodgkin lymphoma, it is often delivered as part of the BEACOPP regimen that includes bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine (tradename Oncovin), prednisone, and procarbazine. The first combination chemotherapy developed for Hodgkin lymphoma (HL), MOPP also included procarbazine (ABVD has supplanted MOPP as standard first line treatment for HL, with BEACOPP as an alternative for advanced/unfavorable HL). Alternatively, when used to treat certain brain tumors (malignant gliomas), it is often dosed as PCV when combined with lomustine (often called CCNU) and vincristine. WP
Dose is adjusted for kidney disease or liver disease. WP
Risks and side effects
Side effects
Very common (greater than 10% of people experience them) adverse effects include loss of appetite, nausea and vomiting. Other side effects of unknown frequency include reduction in leukocytes, reduction in platelets, reduction in neutrophils, which can lead to increased infections including lung infections; severe allergy-like reactions that can lead to angioedema and skin reactions; lethargy; liver complications including jaundice and abnormal liver function tests; reproductive effects including reduction in sperm count and ovarian failure.[2] WP
When combined with ethanol, procarbazine may cause a disulfiram-like reaction in some people.[2] WP
It weakly inhibits MAO in the gastrointestinal system, so it can cause hypertensive crises if associated with the ingestion of tyramine-rich foods such as aged cheeses; this appears to be rare.[2] WP
Procarbazine rarely causes chemotherapy-induced peripheral neuropathy, a progressive, enduring, often irreversible tingling numbness, intense pain, and hypersensitivity to cold, beginning in the hands and feet and sometimes involving the arms and legs.[7]
Median lethal dose (LD50) in animals
Quoted from PubChem's Non-Human Toxicity Values, which come from the Hazardous Substances Data Bank (HSDB). PubChem describes them as: “Quantitative non-human toxicity values (e.g., lethal dose) for this compound. The data shown here are mostly for lab animals (e.g., rat, mouse, guinea pig, and rabbit).” and defines the “LD50 (median lethal dose, the estimated amount of a chemical expected to kill 50% of test animals in a single dose)”. PC
| LD50 (as the source gives it) | Reference |
|---|---|
| LD50 Rat IV 600 mg/kg body weight (at day 59) PC | PMID:8252196; Johnson FE et al; Surg Oncol 2 (1): 77-81 (1993) (via HSDB record 3250) |
Pharmacology
Pharmacology
Procarbazine works, in part, as an alkylating agent and methylates guanine at the O-6 position (much like dacarbazine also does). Guanine is one of the four nucleotides that makes up DNA. The methylated DNA is prone to breakage, and RNA and protein synthesis is inhibited. Proliferating cancer cells need to replicate their DNA and undergo programmed cell death (apoptosis) in response to DNA strand breaks. Normal or non-proliferating cells are more apt to repair the DNA damage, but still some of the healthy cells will be damaged. Procarbazine is metabolized in the liver to an azo-derivative and then further metabolized by the cytochrome P-450 system to an active azoxy-derivative.[9]
Chemistry
Harm reduction information
No harm reduction data is on file for this compound yet. That means no dose, timing or combination data from PsychonautWiki or TripSit. Please don't guess a dose from similar compounds. If you have taken it and feel unwell, contact emergency services or a poison control center.
User reports
Erowid erowid.org
ListingsBluelight bluelight.org
ListingsReddit reddit.com
ListingsPop culture
No references added yet.
Add a reference
Registered users can add songs, films, books, shows, games and art about this substance. Link a source that names the substance, such as the work's Wikipedia article, a review or an interview, not only the work itself. Entries are voted on and moderated like every other value on this page.
Opens when accounts launch.
Sources
- Other Procarbazine Hydrochloride
- Other Procarbazine Capsules 50mg – Summary of Product Characteristics. 24 November 2014
- Other WHO Model Formulary 2008. 2009
- Other British national formulary: BNF 69. 2015
- Other World Health Organization model list of essential medicines: 21st list 2019. 2019
- Other World Health Organization model list of essential medicines: 22nd list (2021). 2021
- Journal / agency DeAngelis LM, Posner JS. Holland-Frei Cancer Medicine. 2003
- Journal / agency del Pino BM. Chemotherapy-induced Peripheral Neuropathy. NCI Cancer Bulletin. Feb 23, 2010
- Journal / agency Mauz-Körholz C, Hasenclever D, Dörffel W, Ruschke K, Pelz T, Voigt A, Stiefel M, Winkler M, Vilser C, Dieckmann K, Karlén J, Bergsträsser E, Fosså A, Mann G, Hummel M, Klapper W, Stein H, Vordermark D, Kluge R, Körholz D. Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study. Journal of Clinical Oncology. August 2010. doi:10.1200/JCO.2009.26.9381 · PMID 20625128
- Journal / agency Newton H. Handbook of Brain Tumor Chemotherapy. 2006
Text and values on this page are quoted from Wikipedia (CC BY-SA 4.0), PubChem (public domain). Each value links to the exact revision it came from.